The American strategy on Ebola is two-pronged: step up desperately needed aid to West Africa and, in an unusual step, train U.S. doctors and nurses for volunteer duty in the outbreak zone. At home, the goal is to speed up medical research and put hospitals on alert should an infected traveler arrive.
DARPA’s new Electrical Prescriptions (ElectRx) program was among the initiatives the White House highlighted this week as President Barack Obama addressed the need for new and more effective strategies for improving the health of service members, veterans and others. ElectRx goes beyond medication, aiming to explore neuromodulation of organ functions to help the human body heal itself.
A number of leading international researchers, among others from the National Food Institute, Technical University of Denmark, have recommended that fluorochemicals should only be used where absolutely essential, until better methods exist to measure the chemicals and more is known about their potentially harmful effects.
Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease. The Indianapolis-based company announced initial results from the research on Thursday and said it plans to submit the drug, ixekizumab, to regulators in the first half of next year.
British drugmaker AstraZeneca says the U.S. Dept. of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action. The company announced in October 2013 that federal officials were looking into the 18,000-patient study, which began in 2009.
A federal panel says older Americans should start getting a new vaccine against bacteria that cause pneumonia. The Advisory Committee on Immunization Practices voted Wednesday to recommend a dose of the expensive new shot for people 65 and older. The panel said older adults should still get an older pneumococcal vaccine, too.
The Food and Drug Administration has approved the first screening test for colon cancer that uses patient DNA to help spot potentially deadly tumors and growths. The Cologuard test from Exact Sciences detects irregular mutations in a patient's stool sample that can be an early warning sign of cancer. Patients who test positive for the mutations should undergo a colonoscopy to confirm the results.
The use of an experimental drug to treat two Americans diagnosed with Ebola is raising ethical questions about who gets first access to unproven new therapies for the deadly disease. But some health experts fear debate over extremely limited doses will distract from tried-and-true measures to curb the growing outbreak.
A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than three million Americans. In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health.
Veterans, medical marijuana activists and scientists welcomed the first federally approved research into pot as a treatment for post-traumatic stress disorder. But their hopes for the research were dashed when the Univ. of Arizona fired researcher Suzanne Sisley, who undertook the study after clearing four years of bureaucratic hurdles.
According to recent research in the U.K. , use of electronic health records to understand the best available treatment for patients, from a range of possible options, is more efficient and less costly for taxpayers than the existing clinical trial process.
Imagine a low-cost treatment for a life-threatening infection that could cure up to 90% of patients with minimal side effects, often in a few days.It may sound like a miracle drug, but this cutting-edge treatment is profoundly simple—though somewhat icky: take the stool of healthy patients to cure those with hard-to-treat intestinal infections.
When it comes to flu vaccines, a federal panel says a squirt in the nose is better than a shot in the arm for young children. The advisory panel agreed Wednesday to tell doctors that FluMist nasal spray is a bit better at preventing flu in healthy young kids. The advice is specific to children ages 2 through 8.
Federal regulators want to hear from companies using engineered micro-particles in their products, part of an effort to stay abreast of the growing field of nanotechnology. The U.S. Food and Drug Administration issued final recommendations Tuesday for companies using nanotechnology in products regulated by the government, which can include medical therapies, food and cosmetics.
The government's top drug abuse experts are struggling to find ways to expand use of a medicine widely considered the best therapy for treating heroin and painkiller addiction, but which remains underused. Senator Carl Levin of Michigan on Wednesday pressed government officials and agencies to increase access to the buprenorphine, a drug which helps addicts control drug cravings and withdrawal symptoms.
Much as human DNA can be used as evidence in criminal trials, genetic information about microorganisms can be analyzed to identify pathogens or other biological agents in the event of a suspicious disease outbreak. The tools and methods used to investigate such outbreaks belong to the new field of microbial forensics, but the field faces substantial scientific and technical challenges, says a new report from the National Research Council.
Patients who use medical marijuana for pain and other chronic symptoms can take an unwanted hit: Insurers don't cover the treatment, which costs as much as $1,000 a month. Once the drug of choice for hippies and rebellious teens, marijuana in recent years has gained more mainstream acceptance for its ability to boost appetite, dull pain and reduce seizures in everyone from epilepsy to cancer patients.
Federal health regulators have cleared a genetic test from Roche as the first ever U.S.-approved alternative to the Pap smear, the decades-old mainstay of cervical cancer screening. The U.S. Food and Drug Administration approved Swiss-based Roche's cobas HPV test to detect the human Papillomavirus, or HPV, in women 25 and up. HPV causes nearly all cases of cervical cancer.
A 10-year-old girl who died of brain cancer is leaving a legacy for other sick children in a new law signed by President Barack Obama. The legislation calls for eliminating taxpayer funding for political conventions and redirecting it to pediatric research at the National Institutes of Health.
Novartis said it's cutting off late-stage research into a potential chronic heart failure treatment because the drug has proven so effective, sending shares to an all-time high when markets opened Monday. Patients taking its twice-daily pill labeled LCZ696 lived longer without being hospitalized for heart failure than those who received a standard of care, Novartis said.
Over the past 20 years, the number of laboratory tests available to primary care physicians has doubled, to more than 3,500 tests, and physicians are challenged by the quantity of tests available. A recent survey conducted by the U.S. Centers for Disease Control and Prevention suggests they often face uncertainty in ordering and interpreting clinical laboratory tests, and would welcome better electronic clinical decision support tools.
Databanks containing information and biological materials from individuals are a crucial resource for research, but they are currently accessible only to researchers. In a recent paper published in Science, experts say that donors should have unrestricted access to data derived from their own material and that advanced technology means allowing such access is today a question of will rather than feasibility.
After 20 years, the nutrition facts label on the back of food packages is getting a makeover. Knowledge about nutrition has evolved since the early 1990s, and the U.S. Food and Drug Administration (FDA) says the labels need to reflect that. Nutritionists and other health experts have their own wish list for label changes.
Many patients and physicians assume that the safety and effectiveness of newly approved drugs is well understood by the U.S. Food and Drug Administration (FDA). But a new study by researchers at Yale School of Medicine shows that the clinical trials used by the FDA to approve new drugs between 2005 and 2012 vary widely in their thoroughness.
Although complications from surgical care for cancer patients may seem infrequent, the costs associated with such outcomes are extremely high, according to researchers from Rice Univ.’s Baker Institute for Public Policy and the Univ. of Texas MD Anderson Cancer Center.